beta-Cadrene is a sparsely documented sesquiterpene hydrocarbon name that appears in some essential-oil composition tables, including a hinoki false cypress record already present in the AromaForge archive. In this research pass, identity support for the exact name was weaker than for many other constituents: the archive occurrence could be confirmed from a public GC analysis, but major public chemistry databases checked here did not cleanly resolve beta-cadrene as a separate named compound. That makes beta-cadrene suitable for a cautious archive entry focused on occurrence and nomenclature uncertainty rather than standalone wellness claims.
Chemical identity and composition
The local archive already uses beta_cadrene in the hinoki-false-cypress oil record at 4.71% based on a public Good Scents GC transcription. However, live lookups on PubChem and the NIST WebBook for the exact name beta-cadrene returned no direct match in this pass. This record therefore preserves the archive constituent id, leaves CAS null, and labels the identity uncertainty explicitly instead of normalizing it to a different sesquiterpene name without a primary source.
Aroma and practical use
- Use the recorded woody, dry, coniferous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A public Typical G.C. analysis for Chamaecyparis obtusa leaf oil listed beta-, cadrene at 4.71% among the sesquiterpene components of the hinoki false cypress profile.
A public Typical G.C. analysis for Chamaecyparis obtusa leaf oil listed beta-, cadrene at 4.71% among the sesquiterpene components of the hinoki false cypress profile.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A review of Thymus broussonetii chemistry included beta-cadrene among reported volatile constituents, supporting that the name does occur in secondary essential-oil literature even though authoritative database resolution was weak in this pass.
A review of Thymus broussonetii chemistry included beta-cadrene among reported volatile constituents, supporting that the name does occur in secondary essential-oil literature even though authoritative database resolution was weak in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific safety assessment, dermal limit, or human tolerability data for the exact name beta-cadrene was located in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because exact identity resolution is incomplete, any downstream interpretation should avoid borrowing safety or mechanism claims from similarly named sesquiterpenes without a primary source match.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- A confident CAS number for the exact name beta-cadrene was not verified from the reviewed public primary databases.
- No isolated-constituent mechanism, bioactivity, or toxicology literature specific to beta-cadrene was located in this pass.
- This record may reflect an unresolved naming, transcription, or structural-isomer issue in historical GC reporting.
- A dedicated safety-focused search pass (IFRA dermal limit, sensitization, phototoxicity, RIFM/CAS lookups) found no IFRA Standard, RIFM fragrance ingredient safety assessment, or Tisserand & Young monograph for beta-cadrene, consistent with the unresolved identity noted above; the previously recorded dermal_limit_pct value of 25 was an unsourced placeholder and has been cleared rather than left silently 'verified'.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.